Search research articles
Contact Us
Filters
Showing results (111-120 of 136) with videos related to
Page
of 14
Sort By:
Clinical Lung Cancer
|
April 4, 2015
Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform
David R Gandara, Philip C Mack, Carol Bult, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 4, 2026
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD
J W Riess, H A Yu, X Le, et al.
Journal for Immunotherapy of Cancer
|
February 6, 2025
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types
David R Gandara, Neeraj Agarwal, Shilpa Gupta, et al.
Nature Communications
|
September 1, 2023
Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial
Arta M Monjazeb, Megan E Daly, Guillaume Luxardi, et al.
JTO Clinical and Research Reports
|
April 27, 2026
Durvalumab Plus Chemotherapy in Patients With <i>EGFR</i>-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD
Byoung Chul Cho, Makoto Nishio, Myung-Ju Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD
Sarah B Goldberg, Myung-Ju Ahn, Christina Baik, et al.
Nature Medicine
|
August 25, 2015
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer
Gorjan Hrustanovic, Victor Olivas, Evangelos Pazarentzos, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 10, 2018
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Christian Rolfo, Philip C Mack, Giorgio V Scagliotti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 28, 2023
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC
Kaiwen Wang, Robyn Du, Nathaniel J Myall, et al.
Cancer
|
March 13, 2026
A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950)
Aarti Bhatia, Zhengjia Chen, Yuji Zhang, et al.
Page
of 14
Search research articles
Search
Showing results (111-120 of 136) with videos related to
Sort By:
Page
of 14
Clinical Lung Cancer
|
April 4, 2015
Bridging tumor genomics to patient outcomes through an integrated patient-derived xenograft platform
David R Gandara, Philip C Mack, Carol Bult, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
March 4, 2026
Osimertinib plus datopotamab deruxtecan in patients with EGFR-mutated advanced NSCLC post-progression on first-line osimertinib: ORCHARD
J W Riess, H A Yu, X Le, et al.
Journal for Immunotherapy of Cancer
|
February 6, 2025
Tumor mutational burden and survival on immune checkpoint inhibition in >8000 patients across 24 cancer types
David R Gandara, Neeraj Agarwal, Shilpa Gupta, et al.
Nature Communications
|
September 1, 2023
Atezolizumab plus stereotactic ablative radiotherapy for medically inoperable patients with early-stage non-small cell lung cancer: a multi-institutional phase I trial
Arta M Monjazeb, Megan E Daly, Guillaume Luxardi, et al.
JTO Clinical and Research Reports
|
April 27, 2026
Durvalumab Plus Chemotherapy in Patients With <i>EGFR</i>-Mutated Advanced NSCLC Whose Disease Progressed on First-Line Osimertinib: ORCHARD
Byoung Chul Cho, Makoto Nishio, Myung-Ju Ahn, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 13, 2026
Osimertinib Plus Gefitinib in Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer and EGFR (C797X) Mutation Following First-Line Osimertinib: ORCHARD
Sarah B Goldberg, Myung-Ju Ahn, Christina Baik, et al.
Nature Medicine
|
August 25, 2015
RAS-MAPK dependence underlies a rational polytherapy strategy in EML4-ALK-positive lung cancer
Gorjan Hrustanovic, Victor Olivas, Evangelos Pazarentzos, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
June 10, 2018
Liquid Biopsy for Advanced Non-Small Cell Lung Cancer (NSCLC): A Statement Paper from the IASLC
Christian Rolfo, Philip C Mack, Giorgio V Scagliotti, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
November 28, 2023
Real-World Efficacy and Safety of Amivantamab for EGFR-Mutant NSCLC
Kaiwen Wang, Robyn Du, Nathaniel J Myall, et al.
Cancer
|
March 13, 2026
A phase 1 study of berzosertib (M6620, VX-970) in combination with cisplatin and radiation in patients with locally advanced head and neck squamous cell carcinoma (ETCTN 9950)
Aarti Bhatia, Zhengjia Chen, Yuji Zhang, et al.
Page
of 14